RxDoctor Payments Data

Heather Moury, DO

Neurology · Pittsburgh, PANPI 1073958872

Payments from drug & device makers

$185,985in general payments, 2019–2025

Across 602 payments — averaging $308.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$71K
  • AbbVie$24K
  • Lundbeck LLC$22K
  • Pfizer$21K
  • Biohaven Pharmaceuticals, Inc.$17K
  • Teva Pharmaceuticals USA, Inc.$15K
  • plus $16K from 35 others

What the payments were for

  • Consulting fees$14,2188%
  • Speaking & faculty fees$155,03583%
  • Grants$1290%
  • Travel & lodging$2,7741%
  • Food & beverage$13,3767%
  • Education$4530%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$185,985 in reported general payments places this provider in the 90th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$71,659
Medicare patients
190
Services billed
3,589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant81$104,190
BotoxOnabotulinumtoxina46$74,674
Nurtec OdtRimegepant Sulfate52$69,490
Emgality PenGalcanezumab-Gnlm73$54,266
QuliptaAtogepant48$50,337
Aimovig AutoinjectorErenumab-Aooe44$40,112
BriviactBrivaracetam29$40,015
Ajovy AutoinjectorFremanezumab-Vfrm34$25,090
Ajovy SyringeFremanezumab-Vfrm17$24,966
LamictalLamotrigine16$23,213
Topiramate ErTopiramate14$18,104
ReyvowLasmiditan Succinate19$13,955
Sumatriptan Succinate92$10,661
Levetiracetam283$7,077
Lacosamide57$4,157

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Botox, Qulipta$23,919$229,201175 claims
PfizerNurtec Odt$21,120$69,49052 claims
UCB, Inc.Briviact$462$40,01529 claims
Lilly USA, LLCReyvow$70,706$13,95519 claims
Upsher-smith Laboratories LLCTopiramate$47$2,477162 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →